By George Ongkojoyo 
New research from the University of South Australia has uncovered significant evidence that the oral contraceptive pill and childbearing are powerful factors in reducing the risk of ovarian cancer, a disease often referred to as the "silent killer" due to its vague symptoms and late-stage detection. By utilizing advanced artificial intelligence and machine learning to analyze a vast dataset of more than 220,000 women, researchers found that the use of the contraceptive pill can reduce the risk of developing the disease by up to 43%, particularly when used later in life. These findings, released ahead of World Cancer Day on February 4, provide a potential roadmap for early diagnosis and preventative strategies for one of the most lethal gynecological malignancies.
The Challenge of Ovarian Cancer Detection and Survival
Ovarian cancer remains a formidable challenge for global healthcare systems. Unlike breast or cervical cancer, there are currently no widely available, highly effective screening tests for ovarian cancer, such as a mammogram or a Pap smear. Consequently, the disease is notoriously difficult to identify in its early stages. According to Dr. Amanda Lumsden, a lead researcher at the University of South Australia (UniSA), approximately 70% of ovarian cancer cases are only identified when the cancer has already reached an advanced stage.
This delay in diagnosis has a devastating impact on survival outcomes. When ovarian cancer is caught early, the five-year survival rate exceeds 90%. However, for those diagnosed at an advanced stage, the survival rate drops precipitously to less than 30%. In Australia, the statistics underscore the severity of the issue: in 2023 alone, 1,786 women were diagnosed with the disease, and 1,050 lost their lives to it. It currently stands as the tenth most common cancer among Australian women and the sixth most common cause of cancer-related death.
The UniSA study sought to address this diagnostic gap by identifying specific risk and preventative factors that could lead to earlier interventions. By understanding who is most at risk and why certain factors offer protection, the medical community can move toward a more personalized approach to screening and prevention.
Harnessing Artificial Intelligence and the UK Biobank
To conduct a study of this magnitude, the UniSA research team, supported by the Medical Research Future Fund (MRFF), turned to the UK Biobank. The UK Biobank is one of the world’s most comprehensive health resources, containing detailed genetic and health information from half a million participants. For this specific study, researchers assessed data from 221,732 females who were aged between 37 and 73 at the start of the study.
The sheer volume of data—which included nearly 3,000 diverse characteristics ranging from health records and medication use to diet, lifestyle, physical measurements, and hormonal factors—required the use of sophisticated artificial intelligence. Machine learning specialist Dr. Iqbal Madakkatel explained that AI allowed the team to identify risk factors that might have remained hidden using traditional statistical methods.
"We included information from almost 3,000 diverse characteristics related to health… each measured at the start of the study," Dr. Madakkatel stated. "It was particularly interesting that some blood measures—which were measured on average 12.6 years before diagnoses—were predictive of ovarian cancer risk."
The use of AI in this context represents a shift in how epidemiological research is conducted. By processing thousands of variables simultaneously, the machine learning algorithms could detect subtle patterns in liver enzymes and red blood cell characteristics that correlate with future cancer risk, offering a potential window for early intervention years before clinical symptoms appear.
The Protective Power of the Contraceptive Pill
One of the most striking findings of the study was the significant protective effect of the oral contraceptive pill (OCP). The research indicated that women who had ever used the pill had a 26% lower risk of developing ovarian cancer compared to those who had never used it.
Even more significant was the discovery that the timing of pill use mattered. For women who continued or started using the pill after the age of 45, the risk reduction jumped to 43%. This suggests that the hormonal regulation provided by the pill in the years leading up to menopause may be particularly beneficial in preventing the cellular mutations that lead to ovarian tumors.
The scientific community has long hypothesized why the contraceptive pill offers this protection. The prevailing theory is known as the "incessant ovulation" hypothesis. Every time a woman ovulates, the surface of the ovary is ruptured and then repaired. This constant cycle of inflammation and cellular repair increases the likelihood of genetic errors that can lead to cancer. By suppressing ovulation, the contraceptive pill gives the ovaries a "rest," thereby reducing the cumulative damage to the ovarian epithelium.
Dr. Lumsden noted that these findings raise important questions for future clinical practice. "This poses the question as to whether interventions that reduce the number of ovulations could be used as a potential target for prevention strategies for ovarian cancer," she said.
Reproductive History and Physical Characteristics
The study also reaffirmed and quantified the protective role of childbearing. Researchers found that women who had given birth to two or more children had a 39% reduced risk of developing ovarian cancer compared to women who had not had children. Similar to the contraceptive pill, pregnancy and breastfeeding are periods during which ovulation is suppressed, further supporting the theory that reducing the total number of lifetime ovulations is key to cancer prevention.
Beyond hormonal and reproductive factors, the AI-driven analysis identified several physical and biological markers associated with the disease. The study found that:
- Body Weight and Height: Lower body weight and shorter stature were associated with a lower risk of ovarian cancer. This aligns with existing research suggesting that obesity and high levels of adiposity (body fat) can drive inflammation and hormonal imbalances that promote cancer growth.
- Biomarkers: Specific characteristics of red blood cells and certain liver enzymes in the blood were identified as predictive indicators. Because these markers were present in the blood over a decade before diagnosis, they could eventually form the basis of a new screening blood test.
Chronology of Research and Future Implications
The UniSA study is the result of years of data collection and analysis. The UK Biobank participants were initially recruited between 2006 and 2010, with their health outcomes tracked over the subsequent decade. The findings represent a culmination of this long-term tracking, combined with the recent application of modern machine learning techniques.
As the world prepares for World Cancer Day on February 4, the UniSA team emphasizes that while these findings are a major step forward, they are not yet a final solution. Project Lead Professor Elina Hyppönen highlighted the need for actionable preventative measures.
"It is exciting that our data-driven analyses have uncovered key risk factors for ovarian cancer that can be acted upon," Prof. Hyppönen said. "It is possible that by using the contraceptive pill to reduce ovulations or by reducing harmful adiposity, we may be able to lower the risk of ovarian cancer. But more research is needed to establish the best approaches to prevention, as well as the ways in which we can identify women most at risk."
The implications of the study extend to public health policy and individual patient counseling. For women with a family history of ovarian cancer or those carrying genetic mutations like BRCA1 or BRCA2, the use of the oral contraceptive pill may be discussed not just as a birth control method, but as a proactive chemopreventative tool. Furthermore, the identification of blood-based biomarkers offers hope for a future where a routine blood test could alert doctors to a high risk of ovarian cancer long before a tumor develops.
A New Era in Oncology: Data-Driven Prevention
The University of South Australia’s research marks a significant milestone in the fight against ovarian cancer. By shifting the focus from treatment to prevention and early detection, the study addresses the primary reason why ovarian cancer remains so deadly: its ability to grow undetected.
The integration of artificial intelligence into medical research is proving to be a game-changer. As machine learning models become more refined, the ability to sift through thousands of variables—from lifestyle choices to metabolic signatures—will allow for a level of "precision prevention" that was previously impossible.
For the thousands of women diagnosed with ovarian cancer each year, these findings offer a glimmer of hope. By identifying that common factors like the contraceptive pill and maintaining a healthy weight can drastically alter one’s risk profile, the medical community is one step closer to turning the "silent killer" into a preventable and manageable condition. The goal now remains to translate these high-level data insights into clinical guidelines that can be implemented in doctor’s offices around the world, ensuring that more women are caught in the "90% survival" bracket rather than the "30%."
